Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismax vs Vislube for Dry Eye Disease
NCT06860659Phase 4Enrolling by invitation
- Sponsor
- Ministry of Public Health
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Vismax in dry eye disease (DED) (2 arms), sponsored by Ministry of Public Health. Primary endpoints: Effect of 0.28% Sodium Hyaluronate on corneal epithelial healing at 30 days and Effect of 0.28% Sodium Hyaluronate on reducing tear osmolarity at 60 minutes. Started Sep 2024; status: enrolling by invitation.
02
Drugs
Vismax
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06860659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860659.